Analysts Estimate Report : What to Look Out for Liminal BioSciences (NASDAQ:LMNL)

Earnings results for Liminal BioSciences (NASDAQ:LMNL)

Liminal BioSciences Inc. is expected* to report earnings on 11/12/2020 after market close. The report will be for the fiscal Quarter ending Sep 2020. According to Zacks Investment Research, based on 1 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.76. The reported EPS for the same quarter last year was $-0.96.

Liminal BioSciences last released its earnings results on August 10th, 2020. The reported ($0.86) earnings per share (EPS) for the quarter. The firm earned $0.39 million during the quarter. Liminal BioSciences has generated ($10.94) earnings per share over the last year. Liminal BioSciences has confirmed that its next quarterly earnings report will be published on Thursday, November 12th, 2020.

Analyst Opinion on Liminal BioSciences (NASDAQ:LMNL)

2 Wall Street analysts have issued ratings and price targets for Liminal BioSciences in the last 12 months. Their average twelve-month price target is $21.00, predicting that the stock has a possible upside of 410.95%. The high price target for LMNL is $21.00 and the low price target for LMNL is $21.00. There are currently 2 hold ratings for the stock, resulting in a consensus rating of “Hold.”

There is not enough analysis data for Liminal BioSciences.

Dividend Strength: Liminal BioSciences (NASDAQ:LMNL)

Liminal BioSciences does not currently pay a dividend. Liminal BioSciences does not have a long track record of dividend growth.

Insiders buying/selling: Liminal BioSciences (NASDAQ:LMNL)

In the past three months, Liminal BioSciences insiders have not sold or bought any company stock. Only 14.29% of the stock of Liminal BioSciences is held by institutions.

Earnings and Valuation of Liminal BioSciences (NASDAQ:LMNL

Earnings for Liminal BioSciences are expected to grow in the coming year, from ($2.67) to ($0.66) per share. The P/E ratio of Liminal BioSciences is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Liminal BioSciences is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Liminal BioSciences has a P/B Ratio of 1.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

More latest stories: here